FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014826743> ?p ?o ?g. }

• W3014826743 endingPage "1878" @default.
• W3014826743 startingPage "1874" @default.
• W3014826743 abstract "Abstract Objectives Carbapenem-resistant Pseudomonas aeruginosa (CR-PSA) imposes great limitations on empirical therapeutic choices, which are further complicated by metallo-β-lactamase production. This study evaluated in vitro antimicrobial synergy of ceftolozane/tazobactam in combination with aztreonam and fosfomycin against MDR PSA. Methods MICs were determined by broth microdilution and gradient strips. The effect of ceftolozane/tazobactam+aztreonam and ceftolozane/tazobactam+fosfomycin combinations were tested against 27 MDR PSA isolates carrying blaSPM-1 (n = 13), blaIMP (n = 4), blaVIM (n = 3), blaGES-1 (n = 2) and blaCTX-M-like (n = 2), and 3 isolates with no acquired β-lactamase production detected by gradient diffusion strip crossing (GDSC). Six genetically unrelated SPM-1-producing isolates were also evaluated by time–kill analysis (TKA). Results All CR-PSA isolates harbouring blaSPM-1, blaGES-1 and blaIMP-1 were categorized as resistant to ceftolozane/tazobactam, meropenem and fosfomycin, with 70% being susceptible to aztreonam. Synergism for ceftolozane/tazobactam+fosfomycin and ceftolozane/tazobactam+aztreonam combinations was observed for 88.9% (24/27) and 18.5% (5/27) of the isolates by GDSC, respectively. A 3- to 9-fold reduction in ceftolozane/tazobactam MICs was observed, depending on the combination. Ceftolozane/tazobactam+fosfomycin was synergistic by TKA against one of six SPM-1-producing isolates, with additional non-synergistic bacterial density reduction for another isolate. Aztreonam peak concentrations alone demonstrated a ≥3 log10 cfu/mL reduction against all six isolates, but all strains were within the susceptible range for the drug. No antagonism was observed. Conclusions In the context of increasing CR-PSA and the genetic diversity of resistance mechanisms, new combinations and stewardship strategies may need to be explored in the face of increasingly difficult to treat pathogens." @default.
• W3014826743 created "2020-04-10" @default.
• W3014826743 creator A5000042350 @default.
• W3014826743 creator A5008017212 @default.
• W3014826743 creator A5024344282 @default.
• W3014826743 creator A5050014117 @default.
• W3014826743 creator A5059914416 @default.
• W3014826743 creator A5064908134 @default.
• W3014826743 creator A5088803186 @default.
• W3014826743 creator A5090740872 @default.
• W3014826743 creator A5091005439 @default.
• W3014826743 date "2020-04-02" @default.
• W3014826743 modified "2023-10-01" @default.
• W3014826743 title "In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa" @default.
• W3014826743 cites W1824341632 @default.
• W3014826743 cites W1911629727 @default.
• W3014826743 cites W1964226118 @default.
• W3014826743 cites W1975005758 @default.
• W3014826743 cites W2106617775 @default.
• W3014826743 cites W2107352206 @default.
• W3014826743 cites W2134276906 @default.
• W3014826743 cites W2142343447 @default.
• W3014826743 cites W2152620389 @default.
• W3014826743 cites W2152944378 @default.
• W3014826743 cites W2167896918 @default.
• W3014826743 cites W2303008909 @default.
• W3014826743 cites W2729273873 @default.
• W3014826743 cites W2758044469 @default.
• W3014826743 cites W2781181029 @default.
• W3014826743 cites W2922853445 @default.
• W3014826743 doi "https://doi.org/10.1093/jac/dkaa095" @default.
• W3014826743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32240299" @default.
• W3014826743 hasPublicationYear "2020" @default.
• W3014826743 type Work @default.
• W3014826743 sameAs 3014826743 @default.
• W3014826743 citedByCount "21" @default.
• W3014826743 countsByYear W30148267432020 @default.
• W3014826743 countsByYear W30148267432021 @default.
• W3014826743 countsByYear W30148267432022 @default.
• W3014826743 countsByYear W30148267432023 @default.
• W3014826743 crossrefType "journal-article" @default.
• W3014826743 hasAuthorship W3014826743A5000042350 @default.
• W3014826743 hasAuthorship W3014826743A5008017212 @default.
• W3014826743 hasAuthorship W3014826743A5024344282 @default.
• W3014826743 hasAuthorship W3014826743A5050014117 @default.
• W3014826743 hasAuthorship W3014826743A5059914416 @default.
• W3014826743 hasAuthorship W3014826743A5064908134 @default.
• W3014826743 hasAuthorship W3014826743A5088803186 @default.
• W3014826743 hasAuthorship W3014826743A5090740872 @default.
• W3014826743 hasAuthorship W3014826743A5091005439 @default.
• W3014826743 hasConcept C176947019 @default.
• W3014826743 hasConcept C2777637488 @default.
• W3014826743 hasConcept C2778266534 @default.
• W3014826743 hasConcept C2778897966 @default.
• W3014826743 hasConcept C2779631663 @default.
• W3014826743 hasConcept C2780416669 @default.
• W3014826743 hasConcept C2780950330 @default.
• W3014826743 hasConcept C501593827 @default.
• W3014826743 hasConcept C523546767 @default.
• W3014826743 hasConcept C54355233 @default.
• W3014826743 hasConcept C86803240 @default.
• W3014826743 hasConcept C89423630 @default.
• W3014826743 hasConcept C94665300 @default.
• W3014826743 hasConceptScore W3014826743C176947019 @default.
• W3014826743 hasConceptScore W3014826743C2777637488 @default.
• W3014826743 hasConceptScore W3014826743C2778266534 @default.
• W3014826743 hasConceptScore W3014826743C2778897966 @default.
• W3014826743 hasConceptScore W3014826743C2779631663 @default.
• W3014826743 hasConceptScore W3014826743C2780416669 @default.
• W3014826743 hasConceptScore W3014826743C2780950330 @default.
• W3014826743 hasConceptScore W3014826743C501593827 @default.
• W3014826743 hasConceptScore W3014826743C523546767 @default.
• W3014826743 hasConceptScore W3014826743C54355233 @default.
• W3014826743 hasConceptScore W3014826743C86803240 @default.
• W3014826743 hasConceptScore W3014826743C89423630 @default.
• W3014826743 hasConceptScore W3014826743C94665300 @default.
• W3014826743 hasFunder F4320321091 @default.
• W3014826743 hasIssue "7" @default.
• W3014826743 hasLocation W30148267431 @default.
• W3014826743 hasOpenAccess W3014826743 @default.
• W3014826743 hasPrimaryLocation W30148267431 @default.
• W3014826743 hasRelatedWork W2161621810 @default.
• W3014826743 hasRelatedWork W2166164946 @default.
• W3014826743 hasRelatedWork W278919240 @default.
• W3014826743 hasRelatedWork W2943688157 @default.
• W3014826743 hasRelatedWork W2989108443 @default.
• W3014826743 hasRelatedWork W3014826743 @default.
• W3014826743 hasRelatedWork W3015034288 @default.
• W3014826743 hasRelatedWork W3032865068 @default.
• W3014826743 hasRelatedWork W3132092684 @default.
• W3014826743 hasRelatedWork W4323255797 @default.
• W3014826743 hasVolume "75" @default.
• W3014826743 isParatext "false" @default.
• W3014826743 isRetracted "false" @default.
• W3014826743 magId "3014826743" @default.
• W3014826743 workType "article" @default.